RTP Mobile Logo
Oncology Tumor Panel Series: Part 5 — Ovarian Cancer
Released August 2015

Video excerpts from the fifth in a series of 5 integrated symposia held at the 2015 ONS Annual Congress. Featuring perspectives from Ms Paula J Anastasia, Dr Deborah K Armstrong, Ms Vivian Gonzalez and Bradley J Monk. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

    OVERVIEW OF ACTIVITY
    The management of OC has become more complex thanks in part to early clinical trial results published with both novel cytotoxics and agents targeting distinct signaling pathways, coupled with available data identifying the clinical yet controversial utility of new therapeutic approaches. In 2015 in the United States alone it is estimated the disease will culminate in 21,290 new cases and 14,180 deaths. Standard practice guidelines support the use of maximal cytoreductive surgery, comprehensive staging and primary medical treatment with intraperitoneal and/or intravenous chemotherapy regimens. Patient selection for the method administered is linked to age, current health status and threshold for treatment-induced toxicity.

    Given the high rate of recurrence of OC there is an urgent need to explore alternative therapeutic options. Several biologically targeted agents, including bevacizumab and PARP inhibitors, have been investigated in the up-front setting as potential therapeutic strategies for patients with relapsed disease. The potential benefits of these therapeutic approaches mandate that clinicians be aware of emerging data and knowledgeable of available protocols to effectively counsel patients in this regard. Additionally, a number of novel agents and approaches are being leveraged in an attempt to improve the treatment course for patients with advanced OC. Promising early clinical trial results of novel cytotoxics and agents targeting distinct signaling pathways in patients with current OC suggest that new therapies and regimens with unique side-effect and toxicity profiles may enter the armamentarium of treatment options in the next several years. Oncology nurses play an integral role in supporting patients through therapy and are essential to the successful delivery of systemic anticancer therapy and in the maintenance of patient physical and psychosocial well-being. In order to offer optimal patient care — including the option of clinical trial participation — oncology nurses, nurse practitioners and clinical nurse specialists involved in the care of these patients must be well informed of these advances and the rapidly evolving treatment paradigms for patients with OC.

    These video proceedings from the fifth part of a 5-part integrated CNE curriculum originally held at the 2015 ONS Annual Congress feature discussions with leading OC investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.


    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with OC.

    LEARNING OBJECTIVES

    • Apply existing and emerging research data to the therapeutic and supportive care of patients with OC.
    • Use case-based learning to gain familiarity with new therapeutic strategies for OC in order to facilitate improved counseling for patients.
    • Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of OC.
    • Appreciate the recent FDA approval of olaparib for patients with highly refractory advanced OC, and safely integrate this therapeutic option into clinical practice.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with OC to optimize clinical and quality-of-life outcomes.
    • Recall ongoing trials of investigational approaches and agents in OC, and refer patients and obtain consent for study participation.

    ACCREDITATION STATEMENT

    CNE credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CNE credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program.

    CNE credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Paula J Anastasia, RN, MN, AOCN
    Gyn-Oncology Clinical Nurse Specialist
    Cedars-Sinai Medical Center
    Los Angeles, California

    Speakers Bureau: Eisai Inc, Genentech BioOncology.

    Deborah K Armstrong, MD
    Director, Breast and Ovarian
    Surveillance Service
    Professor of Oncology, Gynecology and Obstetrics
    The Sidney Kimmel Comprehensive
    Cancer Center
    The Johns Hopkins University
    Baltimore, Maryland

    Advisory Committee: Eisai Inc; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech BioOncology, Incyte Corporation, MedImmune Inc, VentiRx Pharmaceuticals Inc; Other Remunerated Activities: Abbott Laboratories, Sanofi.

    Vivian Gonzalez, MSN, NP-C, AOCNP
    Department of Medical Oncology
    City of Hope Comprehensive Cancer Center
    Duarte, California

    No real or apparent conflicts of interest to disclose.

    Bradley J Monk, MD
    Professor and Director
    Division of Gynecologic Oncology
    Vice Chair, Department of Obstetrics and Gynecology
    University of Arizona Cancer Center — Phoenix
    Creighton University School of Medicine at
    Dignity Health St Joseph’s Hospital and Medical Center
    Phoenix, Arizona

    Consulting Agreements: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Cerulean Pharma Inc, Genentech BioOncology, GlaxoSmithKline, Gradalis Inc, Merck, Roche Laboratories Inc, TESARO Inc, Verastem Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Novartis Pharmaceuticals Corporation, TESARO Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2015
    Expiration date: August 2016

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):